DEA proposal would improve access to DaTscan

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - DaTscan
DaTscan is a radiopharmaceutical imaging agent that works by binding to dopamine transporters (DaT) in the brain. A specific marker for DaT, DaTscan produces images that provide visual evidence of the presence of dopamine transporters. Above, abnormal and normal DaTscan exams are portrayed.
Source: GE Healthcare

A recent proposal by the Drug Enforcement Administration (DEA) would give more physicians access to [123l]lofupane (DaTscan), a diagnostic agent that helps make dopamine transporters in the brain visible and could lead to more accurate diagnoses of Parkinson’s.

In its Notice of Proposed Rulemaking (NPRM), the DEA proposed that DaTscan be removed from Schedule II of the Controlled Substances Act (CSA).

“The DEA finds that the facts and all available and relevant data demonstrate that [123I]ioflupane does not possess abuse or dependence potential,” the text of the NPRM said. “Accordingly, the DEA finds that [123I]ioflupane does not meet the requirements for inclusion in any schedule and should be removed from control under the CSA.”

According to the American College of Radiology (ACR)--which advocated for DaTscan’s removal from the CSA--this will improve access to this “important” agent, improving the overall quality of patient care.

This pdf from 2009 from the FDA provides more information about DaTscan.